Literature DB >> 6362935

Glucocorticoid inhibitory action on the response to PHA of residual circulatory lymphocytes in renal transplant patients following immunosuppressive therapy.

P Musiani, F Citterio, N Maggiano, U Pozzetto, L Lauriola, G Luciani, F O Ranelletti, M Castagneto, M Piantelli.   

Abstract

The inhibitory effect of glucocorticoids on the in vitro response to phytohaemagglutinin of the residual circulating T lymphocytes in renal transplant patients during maintenance immunosuppressive therapy with glucocorticosteroids and azathioprine has been investigated. As in normal subjects, the steroid-induced inhibition of transplanted patients' lymphocyte response was inversely correlated with the mitogen concentration used. On the other hand, the response of the various lymphocyte preparations from transplanted patients appeared less inhibited by steroids than the corresponding preparations from normal subjects. The addition to the culture of the adherent cell product interleukin 1 was effective in removing to a similar extent the steroid inhibitory effect on lymphocytes from normal and transplanted subjects. Thus, the lesser inhibitory effect of glucocorticoids on transplanted patient lymphocytes could be explained by the higher percentages of monocytes present in all peripheral blood mononuclear cell preparations. These results suggest that during immunosuppressive therapy with glucocorticoids and azathioprine the residual circulating lymphocytes have a responsiveness to in vitro dexamethasone suppression similar to that of normal peripheral blood lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362935      PMCID: PMC1535789     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

Review 1.  Mechanisms of glucocorticoid action on immune processes.

Authors:  J E Parrillo; A S Fauci
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

2.  Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques.

Authors:  L B Lachman; M P Hacker; R E Handschumacher
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

3.  Differential effects of immunosuppressive drugs on human T, B, and K lymphocytes.

Authors:  F Thomas; J Thomas; G Mendez; R Lower; H M Lee
Journal:  Transplantation       Date:  1977-12       Impact factor: 4.939

4.  Cytochemical identification of monocytes and granulocytes.

Authors:  L T Yam; C Y Li; W H Crosby
Journal:  Am J Clin Pathol       Date:  1971-03       Impact factor: 2.493

5.  Mechanisms of corticosteroid action on lymphocyte subpopulations. III. Differential effects of dexamethasone administration on subpopulations of effector cells mediating cellular cytotoxicity in man.

Authors:  J E Parrillo; A S Fauci
Journal:  Clin Exp Immunol       Date:  1978-01       Impact factor: 4.330

6.  The effect of in vivo hydrocortisone on subpopulations of human lymphocytes.

Authors:  A S Fauci; D C Dale
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

Review 7.  Glucocorticosteroid therapy: mechanisms of action and clinical considerations.

Authors:  A S Fauci; D C Dale; J E Balow
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

8.  Modulation of glucocorticoid inhibitory action on human lymphocyte mitogenesis: dependence on mitogen concentration and T-cell maturity.

Authors:  F O Ranelletti; P Musiani; N Maggiano; L Lauriola; M Piantelli
Journal:  Cell Immunol       Date:  1983-02-15       Impact factor: 4.868

9.  Human thymoma: immunologic characteristics of the lymphocytic component.

Authors:  L Lauriola; N Maggiano; M Marino; A Carbone; M Piantelli; P Musiani
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

10.  In vitro actions of glucocorticoids on murine macrophages: effects on glucose transport and metabolism, growth in culture, and protein synthesis.

Authors:  J M Norton; A Munck
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.